搜索
 > 【OX40 Ligand】重组蛋白信息

OX40 Ligand信息

英文名称:Tumor necrosis factor ligand superfamily member 4
中文名称:OX40配体
靶点别称:CD252,OX40 ligand,OX40L,TNFSF4,Tumor necrosis factor ligand superfamily member 4,Glycoprotein Gp34,TNF Superfamily Member 4,TXGP1,Tax-Transcriptionally Activated Glycoprotein 1 (34kD),Tumor Necrosis Factor (Ligand) Superfamily, Member 4,Tumor Necrosis Fac
上市药物数量:0
临床药物数量:2
最高研发阶段:临床二期

OX40 Ligand 分子别名

OX40L,TNFSF4,CD252,Glycoprotein Gp34,TXGP1

OX40 Ligand 分子背景

Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.

OX40 Ligand 参考文献

OX40 Ligand临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
KY-1005 KY-1005 临床二期 Kymab 自身免疫疾病, 免疫紊乱, 特应性皮炎 详情
mRNA-2416 mRNA-2416; OX40L mRNA - Moderna Therpeutics 临床二期 Moderna Therapeutics 卵巢癌, 实体瘤, 淋巴瘤 详情
anti-cancer mRNA therapeutics (Moderna Therapeutics) MT 004; MT-377; MT-380; MT-513; MEDI-1191; mRNA-2095; mRNA-2752; mRNA-IL12-iTu-I-O 临床一期 Moderna Therapeutics, 阿斯利康 实体瘤, 头颈部鳞状细胞癌, 移行细胞癌, 三阴性乳腺肿瘤, 淋巴瘤, 非霍奇金淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定